Needlestick Injury and Postexposure Prophylaxis
Needlestick injuries are a common occupational hazard in the hospital setting. According to the Centers for Disease Control and Prevention approximately 385,000 hospital-based healthcare workers experience occupational percutaneous injuries annually.
More than 20 blood-borne pathogens might be transmitted from contaminated needles or sharps, including human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV).
II. Identify the Goal Behavior.
Confirm the exposure by defining both the portal of entry and the body fluid known to transmit blood borne pathogens.
The portal of entry must include: percutaneous, mucous membrane or cutaneous exposure with non-intact skin to body fluids known to transmit human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C (HCV).
Body fluids known to transmit HIV are: Blood, semen, vaginal fluids, amniotic fluids, breast milk, cerebrospinal fluid, pericardial fluid, peritoneal fluid, pleural fluid and synovial flood.
Saliva, vomitus, urine, feces, sweat, tears and respiratory secretions
If the exposure does not encompass both the portal of entry and the at risk body fluids listed above, there is no risk of transmission and further evaluation is not required.
III. Describe a Step-by-Step approach/method to this problem.
After any needlestick injury, an affected healthcare worker should:
Wash the area with soap and water immediately.
Seek care in the facilities area responsible for managing occupational exposures.
Healthcare providers should always be encouraged and supported to report all sharps-related injuries to such departments.
Source patient should be identified and evaluated for potentially transmissible diseases, including HIV, HBV, and HCV. Source patient should undergo appropriate serological testing and any indicated antiviral prophylaxis should be initiated for healthcare worker.
Post-exposure prophylaxis should be initiated after evaluation by the appropriate occupational health department. General principles include:
Risk after needlestick: Ranges from 0.3 – 0.9% depending on mechanism of injury.
Post-exposure prophylaxis (PEP): A 28-day course of a combination of three antiretroviral drugs determined on a case-by-case basis. Act as quickly as possible, preferably within hours to initiate prophylaxis.
Risk after needlestick: 0% in healthcare workers previously vaccinated who have developed immunity; 6% to 30% in unvaccinated healthcare workers.
the exposed healthcare workeris known to be immune(e.g., they were told they had a positive response to the vaccine series, as measured by a follow-up hepatitis B surface antibody (HBsAb) titer ≥10 mIU/mL), they are considered to have lifelong immunity and need no hepatitis B testing or treatment.
Post-exposure prophylaxis (PEP):Hepatitis B immunoglobulin (HBIG) alone or in combination with vaccine (if not previously vaccinated) is thought to provide 75-95% protection from HBV infection. Administer preferably within 24 hours, no later than 7 days.
Risk after needlestick: 1.8%.
There is no post-exposure prophylaxis for HCV.
IV. Common Pitfalls.
Treatment initiation of the exposed worker should not be delayed while waiting for test results. Post exposure prophylaxis can be stopped once results are negative.
V. National Standards, Core Indicators and Quality Measures.
The Occupational Safety and Health Adminstration (OSHA) suggests preventive measures to reduce and eliminate needlestick exposures: use of safety device needles with mechanisms such as Self-Sheathing Safety Features, Retractable Technology, Self Blunting Technology or Needleless Connector Systems. OSHA also advises against unsafe needle handling practices such as bending or recapping needles.
If a source patient’s HIV, HBV, and HCV status are unknown, occupational health personnel can interview the patient to evaluate his or her risks and initiate testing. Specific information about the time and nature of exposure should be documented.
When testing is indicated, it should be done following institutional and state-specific exposure control policy and informed consent guidelines. In all situations, the decision to begin antiviral PEP should be carefully considered, weighing benefits of PEP versus the risks and toxicity of treatment.
VII. What’s the Evidence?
If you have questions about appropriate medical treatment for occupational exposures, assistance is available from the Clinicians’ Post Exposure Prophylaxis (PEP) Line at : 1-888-448-4911.
Recommendations for the management of occupational exposures to blood:
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
- Adhering to Cytoreductive Therapy Use May Improve Outcomes in Polycythemia Vera
- FDA, EU Approvals Sought for Split Dose Regimen of Daratumumab for Multiple Myeloma
- Alternate Dosing of Ruxolitinib May Alleviate Anemia in Myelofibrosis
- Hope, Gratitude, and Spirituality: What They Mean to Cancer Patients
- Combined Digital Screening Best for Detecting Breast Cancers
- NCCIH HerbList App Launched to Provide Information on Herbal Products
- Seeking Reliable Information on Herbal Products
- Metformin Use May Improve Survival Outcomes in Bladder Cancer
- Higher Vitamin D Levels Associated With Lower Breast Cancer Risk
- Nurse-Led Program Improves Health, Financial Outcomes in Outpatient Chemotherapy
- Oral Hydration Effectively Reduced Risk of Nephrotoxity After Cisplatin
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- The Efficacy and Tolerance of High Pressure Oxygen Combined With Chemotherapy in Postoperative Patients With Advanced Gastric Cancer
- Hepatocellular Cancer Pain: Impact and Management Challenges
- Serum Albumin May Indicate Prognosis for Survival in Acute Myeloblastic Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|